Long-Term Pharmacotherapy for Opiate (Primarily Heroin) Addiction: Opioid Antagonists and Partial Agonists

作者: M. J. Kreek

DOI: 10.1007/978-3-642-60963-3_15

关键词:

摘要: The action of a specific opioid antagonist is to bind receptors and thus prevent the exogenous opioids. Use such an will normal physiological endogenous opioids at their receptors. first pure which was successfully synthesized, characterized, patented in 1960 by Dr. J. Fishman with M.J. Lewenstein naloxone, alkyl derivative nor-oxymorphone (BLUMBERG et al. 1961; BLUMBERG DAYTON 1974). Naloxone used clinically remains extremely useful management accidental or medical overdose. has very limited systemic bioavailability, less than 3% reaching circulation after oral administration; when it for narcotic overdose (or attempt made use more chronic opiate dependency) direct receptor blockade agonist central nervous system, naloxone must be administered parenterally, ideally, intravenously (KREEK 1973c; KREEK 1983a,b,c, 1984). Although brief sporadic attempts were maintenance treatment addiction, clear that this would not suitable because need parenteral route administration. However, studies using showed could block all effects, moreover, reverse effects both (KOSTERLITZ WATT 1968; VEREBEY MULE 1975; VOLAVKA 1979a,b; MENDELSON 1980; NABER 1981; HARTMAN 1982; 1984; COHEN 1983; CULPEPPER-MORGAN 1991.

参考文章(113)
Munir A. Hussain, Eli Shefter, Naltrexone-3-salicylate (a prodrug of naltrexone): synthesis and pharmacokinetics in dogs. Pharmaceutical Research. ,vol. 5, pp. 113- 115 ,(1988) , 10.1023/A:1015944302567
Dole Vp, Kreek Mj, Nyswander Me, Narcotic blockade--a medical technique for stopping heroin use by addicts. Transactions of the Association of American Physicians. ,vol. 79, pp. 122- 136 ,(1966)
J. Volavka, A. Mallya, J. Bauman, J. Pevnick, D. Cho, D. Reker, B. James, R. Dornbush, Hormonal and other effects of naltrexone in normal men. Advances in Experimental Medicine and Biology. ,vol. 116, pp. 291- 305 ,(1979) , 10.1007/978-1-4684-3503-0_17
Kleber Hd, Morgan C, Kosten Tr, Phase II clinical trials of buprenorphine: detoxification and induction onto naltrexone. NIDA research monograph. ,vol. 121, pp. 101- 119 ,(1992)
Kogan Mj, Verebey K, Mule Sj, Estimation of the systemic availability and other pharmacokinetic parameters of naltrexone in man after acute and chronic oral administration. Research communications in chemical pathology and pharmacology. ,vol. 18, pp. 29- 34 ,(1977)
A T McLellan, I C Arndt, C P O'Brien, R A Greenstein, B Evans, Naltrexone: a clinical perspective. The Journal of Clinical Psychiatry. ,vol. 45, pp. 25- 28 ,(1984)
A Cohen, R B Resnick, N Flood, P Grandison, C Pycha, M Galanter, Buprenorphine: an alternative to methadone for heroin dependence treatment. Psychopharmacology Bulletin. ,vol. 28, pp. 109- 113 ,(1992)
Bolger G, Weissman Ba, Michel Me, Binding of a new opiate antagonist, nalmefene, to rat brain membranes. Methods and Findings in Experimental and Clinical Pharmacology. ,vol. 7, pp. 175- 177 ,(1985)
JW Lewis, DS Walter, Buprenorphine--background to its development as a treatment for opiate dependence. NIDA research monograph. ,vol. 121, pp. 5- 11 ,(1992)